Steven A. Feldman
Center for Cancer Research
National Cancer Institute
United States of America
Dr. Feldman received his B.A., M.P.H., and Ph.D. from University of California, Berkeley. As a National Reseach Council fellow, he studied mechanisms of viral entry at the FDA's Centers for Biologics Evaluation and Research followed by an addtional NIH fellowhsip investigating the mechanisms of retroviral entry into host cells. Dr. Feldman then spent three years at a leading biotechnology company as the Senior Scientist in charge of process development for the manufacturing of viral vectors and vaccines before coming back to the Surgery Branch of the National Cancer Institute to establish a new Retro/Lentiviral Vector Core Facility.
immunotherapy, gene therapy, adoptive cell therapy, viral vector development, cell line development, cGMP manufacturing
Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA. A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Human Gene Therapy, Part B: Methods. 2012 Mar 19;23(2):73-83.
Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term follow-up and correlates with response. Clinical Cancer Research. 2015 Mar 1;21(5):1019-27.
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet. 2015 Feb 13;385(9967):517-28.